43766 Cumulative clinical benefit over 52 weeks comparing initiation with deucravacitinib versus apremilast in patients with moderate to severe plaque psoriasis: a post hoc analysis of POETYK PSO-1 trial results stratified by prior treatment
- Resource Type
- Abstract
- Source
- In
Journal of the American Academy of Dermatology September 2023 89(3) Supplement:AB30-AB30 - Subject
- Language
- ISSN
- 0190-9622